A coalition of scientific researchers has initiated a major class-action lawsuit against the National Institutes of Health, accusing the Trump administration of orchestrating an unconstitutional campaign of censorship by canceling and withholding critical biomedical research grants. The legal action, filed in federal court in San Francisco, targets the government's policy of systematically suppressing scientific subjects that do not align with its ideological positions.
According to the complaint, federal officials instituted a screening mechanism utilizing an expansive list of 235 prohibited keywords, including terms such as "gender" and "racist." This keyword-based filtering system has reportedly been deployed across the agency to block federal support for a broad array of scientific inquiry, impacting vital research areas ranging from public health equity initiatives to studies examining the health impacts of climate change.
The targeted agency, the National Institutes of Health, operates under the Department of Health and Human Services and stands as the foremost public financier of biomedical studies in the world. Because of its central role in underwriting scientific discovery, the administration's sudden implementation of ideological keyword restrictions has sent shockwaves through the American academic and medical research landscapes.
The legal challenge has garnered substantial backing from prominent civil rights and scientific advocacy organizations, including the American Civil Liberties Union and the Center for Science in the Public Interest. The plaintiffs argue that using ideological litmus tests to determine scientific merit constitutes a direct violation of the First Amendment, which prohibits the federal government from suppressing protected speech simply because officials dislike the viewpoints expressed.
Legal representatives from the ACLU emphasized that federal research financing is being converted into a political weapon intended to silence disfavored perspectives. Olga Akselrod, a senior counsel with the ACLU's Racial Justice Program, asserted that the administration's actions are placing extraordinary pressure on scientists to censor their own projects or face the immediate loss of funding whenever their research might produce results that contradict official ideology.
Akselrod pointed out that while the funding agency inherently possesses the authority to make broad decisions regarding which research topics to support, such determinations must strictly adhere to existing governing statutes, established administrative regulations, and constitutional guarantees. She underscored that federal officials cannot legally exclude research proposals or academic applicants solely out of concern that the investigators might voice perspectives at odds with the administration's platform.
For decades, federal biomedical grants have been distributed through a structured scientific peer-review framework, where independent panels of experts evaluate proposals based on technical soundness, methodology, and public health impact. This established process was designed to provide scientists with a predictable, multi-year funding pathway necessary for long-term discovery, shielding scientific work from shifting political currents and ideological interference.
That stable grantmaking environment shifted dramatically in 2025 when the administration initiated sweeping cancellations of thousands of research awards throughout the federal government. According to tracking data compiled by the monitoring organization Grant Witness, these widespread cancellations threw more than 5,700 NIH-funded research grants into operational turmoil, although more than 4,500 of those disrupted awards have since been reinstated following pushback and legal scrutiny.
The newly filed class-action litigation aims to secure comprehensive relief for all scientists whose research grants remain canceled without court-ordered restoration. The lawsuit also seeks to represent primary investigators across the country who have experienced severe project delays, outright funding denials, or forced renegotiations of their award terms due to the administration's ideological screening measures.
Among the researchers affected by the policy is Ann Cohen, an associate professor of psychiatry affiliated with the University of Pittsburgh. Cohen led a dedicated scientific project focused on Alzheimer's disease, specifically examining innovative methods to identify and mitigate dementia risks within vulnerable and historically understudied demographic groups that face disproportionately high risks of developing the condition.
Cohen explained that her investigative team had spent more than a decade establishing essential trust and engagement with communities that are routinely overlooked in medical research. The sudden revocation of her grant funding forced the research team to abruptly call off scheduled participant appointments, prevented subjects from accessing promised diagnostic data, and stalled critical analytical pipelines, placing years of hard-won scientific progress and community trust in serious jeopardy.
Another named plaintiff, Dr. Arghavan Salles, a surgeon and clinical associate professor in Stanford University's Department of Medicine, shared similar experiences of professional disruption and administrative obstruction. Salles has dedicated more than fifteen years of scholarly work to investigating gender equity, workplace sexual harassment, and the structural obstacles that force qualified professionals out of scientific and medical disciplines.
Salles noted that the administration's 235-keyword filter has made it virtually impossible to accurately articulate the scope and importance of her research. Standard academic terms central to her field—such as "equity," "gender," and "sexual harassment"—are now treated as red flags that trigger grant disqualification for being inconsistent with current administrative directives, forcing researchers into an untenable posture of self-censorship.
The plaintiffs contend that forcing researchers to scrub and sanitize their proposals undermines both scientific integrity and the substantial financial investments already made by American taxpayers over multiple years of inquiry. Representatives for the Department of Health and Human Services, the cabinet-level parent agency overseeing the National Institutes of Health, did not immediately provide comment regarding the allegations outlined in the lawsuit.
(0)